Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays

JAMA Dermatol. 2014 Aug;150(8):901-3. doi: 10.1001/jamadermatol.2013.9411.

Authors

Momen Pharaon¹, Mélanie Tichet², Christine Lebrun-Frénay³, Sophie Tartare-Deckert², Thierry Passeron⁴

Affiliations

¹ Department of Dermatology, Archet 2 Hospital, Centre Hospitalier Universitaire (CHU) Nice, Nice, France.
² Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 11, Centre Méditerranéen de Médecin Moléculaire (C3M), Nice, France.
³ Department of Neurology, Pasteur Hospital, CHU Nice, Nice, France.
⁴ Department of Dermatology, Archet 2 Hospital, Centre Hospitalier Universitaire (CHU) Nice, Nice, France4INSERM, U1065, Team 12, C3M, Nice, France.

PMID: 24919481
DOI: 10.1001/jamadermatol.2013.9411

No abstract available

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Cell Line, Tumor
Cell Movement / drug effects
Cell Proliferation / drug effects
Cell Transformation, Neoplastic
Dermoscopy
Follow-Up Studies
Humans
Immunohistochemistry
Immunologic Factors / pharmacology*
Integrin beta3 / analysis
Melanoma / chemistry
Melanoma / pathology*
Multiple Sclerosis / drug therapy
Natalizumab
Nevus / chemistry
Nevus / pathology*
Osteonectin / analysis
Skin Neoplasms / chemistry
Skin Neoplasms / pathology*

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Integrin beta3
Natalizumab
Osteonectin
SPARC protein, human